Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nippon Chemiphar Co., Ltd. (4539.T)
Tokyo, JP
Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.36% | +0.42% | -2.58% | -10.10% | +9.11% | +5.92% | +14.05% | -8.37% | -27.68% | -66.38% | -27.34% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1.6% Q1'26: +6.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-32.8% Q1'26: -134.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-0.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.5% Q1'26: -0.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.5% Q1'26: -0.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.2% Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×9.54× Q1'26: 10.60× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
|---|---|
| Revenue |
35.12B
est: 40.10B (-12.4%)
|
| EBITDA |
8.16B
est: 2.58B (+216.6%)
|
| EBIT |
3.25B
est: 731.17M (+344.6%)
|
| Net Income |
1.90B
est: 784.05M (+142.2%)
|
| SGA |
11.73B
est: 8.77B (+33.6%)
|
| EPS |
474.35
est: 217.30 (+118.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kazushiro Yamaguchi | Chairman, Chief Executive Officer & President | 119M | male |
| Hirofumi Miyata | Corporate Officer & GM of Human Resources | — | — |
| Kouki Hayamizu | Executive Officer, Head of Development Planning & Director | — | male |
| Masahide Yasumoto | Ops., Info. Sys. Dept., Pub. Rel., Lab. Drugs, Corp. Plan., Mgr., Sr. Managing Corp. Offr.& Dir. | — | male |
| Shinichi Kudo | Corporate Officer | — | — |
| Shinji Nakajima | Corporation Officer, GM of Group Purchasing & Sales Mgmt. Center, Administration Dept. Manager & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4539.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
